ApotheCom San Francisco California USA

Department of Cardiovascular Sciences University of Leicester Leicester UK

Department of Nephrology Charles University and General University Hospital Prague Czech Republic

Department of Nephrology Stanford University Stanford California USA

Division of Nephrology and Dialysis Department of Pediatric Subspecialties Bambino Gesù Pediatric Hospital Istituto di Ricerca e Cura a Carattere Scientifico Rome Italy

Division of Nephrology and Immunology Rheinisch Westfälische Technische Hochschule Aachen Aachen Germany

Division of Nephrology Columbia University Medical Center New York New York USA

Division of Nephrology Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA

Division of Nephrology Department of Medicine University Health Network and University of Toronto Toronto Ontario Canada

Division of Pediatric Nephrology Department of Pediatrics Medical University of South Carolina Charleston South Carolina USA

Fondazione Ricerca Molinette Regina Margherita Hospital Turin Italy

See more in PubMed

Barbour S., Feehally J. An update on the treatment of IgA nephropathy. Curr Opin Nephrol Hypertens. 2017;26:319–326. doi: 10.1097/MNH.0000000000000336. PubMed DOI

Rauen T., Wied S., Fitzner C., et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98:1044–1052. doi: 10.1016/j.kint.2020.04.046. PubMed DOI

Rauen T., Eitner F., Fitzner C., et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–2236. doi: 10.1056/NEJMoa1415463. PubMed DOI

Lv J., Zhang H., Wong M.G., et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–442. doi: 10.1001/jama.2017.9362. PubMed DOI PMC

V. Perkovic, J. Lv, M.G. Wong, et al., The TESTING study: steroids vs. placebo in high risk IgA nephropathy. Presented at Kidney Week 2021; November 5, 2021. Virtual. Abstract FR-OR61.

Fogo A.B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11:76–87. doi: 10.1038/nrneph.2014.216. PubMed DOI PMC

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group workgroup KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1–S276. doi: 10.1016/j.kint.2021.05.021. PubMed DOI

Gutiérrez E., Carvaca-Fontán F., Luzardo L., et al. A personalized update on IgA nephropathy: a new vision and new future challenges. Nephron. 2020;144:555–571. doi: 10.1159/000509997. PubMed DOI

FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. US Food and Drug Administration. https://www.fda.gov/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease Updated December 17, 2021.